vTv Therapeutics
VTVT
37 hedge funds and large institutions have $20.4M invested in vTv Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 7 closing their positions.
13% more capital invested
Capital invested by funds: $18M → $20.4M (+$2.42M)
0.05% less ownership
Funds ownership: 0.94% → 0.88% (-0.05%)
5% less funds holding
Funds holding: 39 → 37 (-2)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$412K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$18.5K |
| 3 |
BlackRock
New York
|
+$13.6K |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$13.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$454K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$282K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$198K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$145K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$125K |
VTVT Hedge Fund Activity: Q3 2017 in Review
37 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2017, worth a combined $20.4M — up 13% from $18M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VTVT and 5 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $412K. The largest seller was Ameriprise, cutting an estimated $454K.
- 37 institutional investors held vTv Therapeutics (VTVT) as of Q3 2017, down from 39 in Q2 2017.
- Funds reported $20.4M of vTv Therapeutics stock for Q3 2017, up 13% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q3 2017 and 7 closed out, a net change of -2 holders.
- The largest vTv Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $412K added.
- The largest vTv Therapeutics seller in Q3 2017 was Ameriprise, an estimated $454K sold.
Based on aggregated 13F filings for Q3 2017.